A Look at Johnson & Johnson’s Major Developments since 2Q17
A look at Johnson & Johnson
Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies. Its headquarters are in New Brunswick, New Jersey, and it operates in over 200 countries worldwide.
Interested in JNJ? Don't miss the next report.
Receive e-mail alerts for new research on JNJ
Some of the major developments for Johnson & Johnson since 2Q17 are as follows:
- On September 22, 2017, the US Food and Drug Administration (or FDA) gave its complete response letter to Janssen Biotech for the Biologics License Application of Sirukumab for the treatment of rheumatoid arthritis.
- On September 16, 2017, Johnson & Johnson released long-term data from VOYAGE-1, a study evaluating Tremfya. The results showed an 80% consistent rate of skin clearance in patients with moderate-to-severe plaque psoriasis.
- On September 15, 2017, the European Medicines Agency’s (or EMA) Committee for Medicinal Products for Human Use (or CHMP) gave a positive opinion for Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
- On September 15, 2017, Johnson & Johnson announced a collaboration with the US Department of Health and Human Services to develop a portfolio of drugs and vaccines for influenza and other infectious disease threats.
- On September 14, 2017, Johnson & Johnson submitted a supplemental new drug application to the US FDA for approval of Zytiga in combination with prednisone and androgen deprivation therapy for the treatment of metastatic hormone naïve prostate cancer.
- On September 11, 2017, Janssen announced the decision to discontinue the development of JNJ-4178, an investigational hepatitis C regimen, which is a combination of three antivirals including AL-335, simeprevir, and odalasvir. The decision was made with increasing hepatitis C therapies in the market.
- On September 6, 2017, the US FDA approved Tracleer (bosentan) for the treatment of pediatric patients with pulmonary arterial hypertension.